Skip to main
CRBP
CRBP logo

CRBP Stock Forecast & Price Target

CRBP Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Corbus Pharmaceuticals Holdings Inc. is positioned favorably with its development pipeline, especially with CRB-701, which is showing promise as a derisked, multi-indication antibody-drug conjugate (ADC) backed by its competitive efficacy and superior tolerability. The anticipation of upcoming dose optimization data from the Phase 1/2 study at ESMO 2025 could enhance its clinical trajectory, potentially leading to additional designations that would expedite its development. Historical precedents in the industry, such as the accelerated approvals seen with other drugs, suggest that the company's strategic alignment with regulatory pathways might streamline its timeline for product approvals, signaling robust growth potential.

Bears say

Corbus Pharmaceuticals Holdings Inc faces significant risks associated with its clinical trials, as the potential for its drug candidates to fail in demonstrating meaningful efficacy could adversely affect investor confidence and the overall share price. Additionally, the company may encounter challenges in achieving timely regulatory approvals, and any delays in this area could further depress its market valuation. Concerns over maintaining a strong safety profile for its drugs, particularly with respect to the historical adverse events associated with antibody-drug conjugates, may also contribute to skepticism from key opinion leaders, ultimately impacting the company's financial outlook.

CRBP has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corbus Pharmaceuticals Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corbus Pharmaceuticals Holdings (CRBP) Forecast

Analysts have given CRBP a Buy based on their latest research and market trends.

According to 5 analysts, CRBP has a Buy consensus rating as of Oct 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corbus Pharmaceuticals Holdings (CRBP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.